Shigella
Vaccines Forecast
Shigella still causes an estimated 81,000 or more deaths a year among children under five, and remains the second-leading cause of diarrhoeal mortality worldwide across all ages. Extensively drug-resistant strains, now resistant to all five commonly used first-line antibiotics, are spreading fast across multiple geographies. Against that backdrop, Valneva and LimmaTech's tetravalent S4V2 candidate has become the field's most advanced multivalent programme, now in simultaneous Phase 2 infant and human challenge trials. This is a comprehensive, wide geography commercial assessment of the Shigella vaccine opportunity, drawing on VacZine Analytics' long standing, independent authority in endemic and diarrhoeal disease vaccine markets.
- Format
- PDF (~150 slides) + Excel model
- Markets modelled
- Endemic & traveler
- Scenarios
- LO / BASE / HI pricing
- Forecast horizon
- To 2035
- Approach
- Value/volume demand model
- Base edition
- March 2018
- Availability
- Syndicated / bespoke
children under five worldwide
in developing countries
extensively drug-resistant
available today
A revised burden estimate, and a resistance problem that keeps worsening
This review sets out the current disease background, global burden and R&D competitive landscape for Shigella, drawing on the latest WHO and Global Burden of Disease data.
Pathogen overview - Shigella spp.
Shigella are highly infectious, Gram-negative, non-sporulating, facultative anaerobic bacteria that produce toxins responsible for shigellosis, an illness marked by fever, headache, malaise, anorexia and, frequently, bloody diarrhoea. While generally self-limiting in otherwise healthy adults, shigellosis in young children can be severe, carrying additional risk of seizures, haemolytic uraemic syndrome and, rarely, encephalopathy. Four species, S. flexneri, S. sonnei, S. boydii and S. dysenteriae, spanning around 50 serotypes, complicate the case for a single, broadly protective vaccine. When VacZine Analytics last published on this market in March 2018, WHO's widely cited 1999 estimate of 164.7 million annual cases and 1.1 million deaths still anchored the field's understanding of disease burden.
That picture has since been substantially revised, though Shigella's ranking among the leading causes of diarrhoeal death has not changed. The Global Burden of Disease study attributes approximately 212,000 deaths across all ages to Shigella annually, around 13% of all diarrhoea-associated deaths, making it the second-leading cause of diarrhoeal mortality worldwide. More recent catalytic estimates put annual deaths among children under five at over 81,000, with the greatest burden falling on low- and middle-income countries, where an estimated 28,000 to 64,000 under-5 deaths occur each year. Ninety-nine percent of Shigella infections occur in developing countries, and around 70% of cases and 60% of deaths occur in children under five, with malnutrition, poor sanitation and crowding as recurring risk factors.
Compounding the disease burden is a fast-worsening antimicrobial resistance picture. WHO lists Shigella among its antibiotic-resistant priority pathogens, and CDC surveillance shows extensively drug-resistant (XDR) Shigella strains, resistant to all five commonly used first-line antibiotics, rising from 0% of US isolates in 2011-2015 to 8.5% nationally by 2023, with some surveillance sites recording a rise from 0% in 2021 to 17% in 2024. No FDA-approved oral antimicrobial treatment currently exists for XDR Shigella infections, sharpening the case for a preventive vaccine. Against that backdrop, a candidate built on the GSK Vaccines Institute for Global Health's (GVGH) GMMA outer-membrane-vesicle platform, licensed to LimmaTech Biologics and partnered with Valneva as the tetravalent S4V2 candidate, has become the field's most advanced multivalent programme. Following a Phase 2b controlled human infection model study in adults that began dosing in November 2024, a Phase 2 infant safety and immunogenicity study started in Kenya in April 2025 (around 110 nine-month-olds); LimmaTech continues to sponsor both studies, and Valneva's August 2026 half-year update now guides to results from both trials in the third quarter of 2026, after which Valneva will decide whether to take over late-stage development itself. WRAIR's live oral WRSs2 and WRSs3 candidates against S. sonnei, evaluated in Phase I trials, continue the cellular-vaccine approach the original 2018 MarketVIEW edition flagged, alongside PATH- and NIH-co-funded conjugate and subunit programmes.
A GMMA-platform tetravalent candidate leads a field racing against resistance
Decades after Shigella was first flagged as a vaccine priority by PATH, WHO and the NIH, a tetravalent candidate built on a proven outer-membrane-vesicle platform has become the field's most advanced multivalent programme yet.
-
LimmaTech Biologics AG / Valneva SEPositive Phase 2 results reported Nov 2026S4V2 (Shigella4V2) Tetravalent GMMA/OMV vaccine
Built on GVGH's Generalised Modules for Membrane Antigens (GMMA) platform, targeting S. sonnei and S. flexneri 2a, 3a and 6. A Phase 2b controlled human infection model study in adults began dosing November 2024, and a Phase 2 infant study of around 110 nine-month-olds started in Kenya in April 2025; LimmaTech continues to sponsor both trials. On 9 November 2026, Valneva announced positive headline results from both, reporting a favourable safety profile with encouraging immunogenicity and efficacy signals, and said it is now evaluating the complete dataset to determine the most appropriate path forward for the candidate. Separately, Eli Lilly agreed in May 2026 to acquire LimmaTech as part of a wider infectious-disease buildout; the announced deal centres on LimmaTech's Staphylococcus aureus and preclinical gonorrhoea/chlamydia programmes, and Valneva's subsequent reporting indicates the Shigella collaboration continues unaffected. -
Walter Reed Army Institute of ResearchPhase I completeWRSs2 / WRSs3 Live attenuated oral candidates
Two live oral candidates targeting S. sonnei, evaluated for safety and immunogenicity in a Phase I trial, continuing WRAIR's decades-long live oral vaccine programme referenced in the original 2018 MarketVIEW edition. -
PATH / NIH-co-funded programmesVarious early- to mid-stageConjugate, subunit & novel antigen candidates
Continued international co-funding, including PATH- and NIH-backed glycoconjugate and protein-subunit programmes, aimed at broadening cross-serotype protection beyond the leading GMMA and live oral platforms. -
WHO / CDC surveillance networksActive AMR surveillanceGlobal Shigella resistance monitoring
Ongoing tracking of extensively drug-resistant (XDR) Shigella strains, which WHO lists among its antibiotic-resistant priority pathogens, informs both vaccine target product profile design and market-access urgency.
Valneva and LimmaTech's advance of the tetravalent S4V2 candidate into simultaneous Phase 2 infant and Phase 2b controlled human infection model studies marks the most credentialed the Shigella vaccine pipeline has been since international agencies first prioritised multivalent vaccine development. That progress arrives just as extensively drug-resistant Shigella strains spread across multiple geographies, reframing the commercial case across endemic paediatric and traveler market segments alike. The VacZine Analytics model quantifies this opportunity under LO/BASE/HI pricing scenarios reflecting differing degrees of pipeline success and country-level disease-incidence risk classification.
Six analytical layers - one commercial picture
This is a genuinely comprehensive report with a wide geographic focus, spanning disease burden, current R&D status and scenario-based demand forecasting across endemic and traveler markets to 2035.
Value ($m) and volume (million doses) forecasts to 2035 across paediatric endemic markets and adult traveler segments.
Full review of Valneva/LimmaTech's S4V2, WRAIR's WRSs2/WRSs3 and the wider Shigella R&D landscape.
Target product profile, launch timeframe assumptions, pricing and market penetration estimates for endemic and traveler segments.
Three pricing-justified revenue scenarios based on a country-level Shigella disease-incidence risk classification.
Global case, death and antimicrobial-resistance surveillance data updated through WHO and GBD's most recent 2025/2026 reporting.
Assessment of rising extensively drug-resistant Shigella prevalence and its implications for treatment guidelines, vaccine TPP and market access.
A glimpse of the commercial model
The table below shows a partial view of the market-segment and scenario framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Market segment | Geography | Sector | Vaccine status | Revenue scenario |
|---|---|---|---|---|
| Endemic - infants & young children | Africa, Asia, Americas | Public/private | Pre-licensure | Modelled |
| Traveler & military/occupational | Global source markets | Private | Pre-licensure | Modelled |
| Outbreak / AMR-driven response | ROW | Public | Pre-licensure | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All geographies | All sectors | All scenarios | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the Shigella vaccine opportunity across endemic and traveler markets.
- Executive presentation (~150 slides, PDF) - disease background, epidemiology, R&D status and full commercial assessment with supporting narrative and references
- MS-Excel forecast model - value ($m) and volume (million doses) predictions to 2035 across endemic and traveler market segments
- LO/BASE/HI pricing scenarios - three forecast scenarios based on a country-level Shigella disease-incidence risk classification
- Competitor intelligence - Valneva/LimmaTech's S4V2, WRAIR's WRSs2/WRSs3 and the wider Shigella R&D landscape
- Updated epidemiology module - WHO/GBD 2025-2026 update covering global burden, under-5 mortality and antimicrobial resistance trends
- TPP, launch timing & penetration estimates - target product profile, launch timeframe and pricing/penetration assumptions for endemic and traveler segments
Built for organisations weighing the Shigella vaccine opportunity
Most valuable to teams evaluating the Shigella vaccine market against their own pipeline, BD ambitions or investment thesis, now that a tetravalent candidate is approaching later-stage trials.
Vaccine developers
Positioning and commercial feasibility assessment for Shigella candidates at any stage, informed by S4V2's advance into Phase 2 infant and challenge trials.
Corporate strategy & BD
Validate the size and structure of a still-open market with no incumbent vaccine, now that a tetravalent GMMA candidate is approaching later-stage trials.
Investors & analysts
Independent assessment of pipeline risk and commercial upside for due diligence on Valneva, LimmaTech and future Shigella entrants.
Public health & global health bodies
Demand modelling and country-level risk classification to support PATH-, WHO- and NIH-aligned Shigella vaccine introduction planning.
Researchers & academia
Comprehensive epidemiology, antimicrobial resistance and R&D landscape for grant, translational and vaccine-platform research planning.
Market access & policy
Pricing benchmarks and access-pathway assumptions across endemic paediatric and traveler channels worldwide.
VacZine Analytics has tracked endemic and diarrhoeal disease vaccine markets since our earliest editions, positioning us to reassess the Shigella vaccine opportunity the moment the field's leading candidate advanced into simultaneous Phase 2 infant and controlled human infection model trials. This is a genuinely comprehensive analysis with a wide geographic focus spanning endemic paediatric and traveler market segments, and it has been well received by clients across the field for the depth of its epidemiology and country-level risk-classification modelling. Few groups have followed this market as closely, and that recognised, independent expertise underpins everything in the analysis.
This March 2018 edition has been further refreshed to incorporate WHO and GBD's most recent 2025-2026 data, updating the disease-burden estimate from the 1999 WHO figure of 1.1 million annual deaths to a current estimate of over 81,000 annual deaths among children under five, alongside the R&D field's advance to Valneva and LimmaTech's Phase 2 S4V2 trials and the accelerating spread of extensively drug-resistant Shigella strains. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Shigella analysis, a briefing call is included on request.